Immatics' T-Cell Redirecting Immunotherapies Impress In Solid Tumors
Quicker Cell Engineering Could Be Key
The promise of Immatics’ T-cell redirecting cancer immunotherapy technology for solid tumors has been spotlighted in early clinical studies in heavily pre-treated and refractory cancer patients.
